bronchiectasis
BRONCHIECTASIS
Bronchiectasis is an irreversible pathologic dilatation or ectasia of the bronchi due to repeated airway infection and inflammation.
It enhances susceptibility to bronchial infection and increases inflammatory reaction which causes further lung damage.
Classic symptoms of of bronchiectasis are cough with chronic sputum production along with recurring infective exacerbations and hemoptysis.
Drug Information

Indication: Short-term treatment of upper & lower resp tract, skin & soft tissue, GUT infections. Tab & inj Sh...

Indication: Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired & nosoco...

Indication: Infections of the resp tract, middle ear (otitis media), paranasal sinuses (sinusitis) especially caused by gm...

Indication: Lower resp tract, complicated & uncomplicated UTI, intra-abdominal, skin & skin structure infections; ...

Indication: Upper & lower resp tract infections, GUT, skin & soft tissue infections, gonorrhoea, acute uncomplicat...

Indication: Upper & lower resp tract, GUT, skin & soft tissue infections, gonorrhoea, acute uncomplicated gonococc...

Indication: Infections due to gm -ve & +ve organisms & non-penicillinase-producing staph.

Indication: Acute & chronic bronchopulmonary diseases associated w/ abnormal mucus secretion & impaired mucus tran...

Indication: Acute & chronic diseases of the resp tract especially chronic bronchitis, asthmatoid bronchitis, bronchial...

Indication: Resp tract, ENT, urinary tract, soft-tissue, bone & joint, O&G infections; pelvic inflammatory disease...

1  /  14
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Patients with chronic obstructive pulmonary disease or bronchiectasis suffer from heightened pain perception, severity and sensitivity, a recent study has found.
Stephen Padilla, 06 Jun 2019
Extended preloading of varenicline for 6 weeks before the target quit day (TQD) safely improves the efficacy of the prescription medication in facilitating smoking cessation at 12 weeks and at 6 months, according to a study presented at the American Thoracic Society (ATS) 2019 International Conference, held at Dallas, Texas in the US.